{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T13:47:07Z","timestamp":1784209627315,"version":"3.55.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1038\/s41375-025-02707-2","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T07:29:48Z","timestamp":1752650988000},"page":"2285-2288","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Evolution of clonal hematopoiesis on and off lenalidomide maintenance for multiple myeloma"],"prefix":"10.1038","volume":"39","author":[{"given":"Jennifer H.","family":"Cooperrider","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diren Arda","family":"Karaoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7588-1453","authenticated-orcid":false,"given":"Tadeusz","family":"Kubicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can Rui","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella","family":"Postich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2732-6495","authenticated-orcid":false,"given":"Kathryn","family":"Shimamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6307-5056","authenticated-orcid":false,"given":"Jommel","family":"Macaraeg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aubrianna","family":"Ramsland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2270-2997","authenticated-orcid":false,"given":"Anna","family":"Pula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin","family":"Kishtagari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yash","family":"Pershad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taralynn M.","family":"Mack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1565-4360","authenticated-orcid":false,"given":"Angela","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5824-9595","authenticated-orcid":false,"given":"Alexander G.","family":"Bick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3763-5504","authenticated-orcid":false,"given":"Michael","family":"Savona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Drazer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Dytfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2597-6822","authenticated-orcid":false,"given":"Andrzej","family":"Jakubowiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4070-1819","authenticated-orcid":false,"given":"Benjamin A.","family":"Derman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7617-8356","authenticated-orcid":false,"given":"Caner","family":"Saygin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,16]]},"reference":[{"key":"2707_CR1","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1158\/2643-3230.BCD-21-0205","volume":"3","author":"FE Davies","year":"2022","unstructured":"Davies FE, Pawlyn C, Usmani SZ, San-Miguel JF, Einsele H, Boyle EM, et al. Perspectives on the Risk-Stratified Treatment of Multiple Myeloma. Blood Cancer Discov. 2022;3:273\u201384.","journal-title":"Blood Cancer Discov"},{"key":"2707_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100757","volume":"46","author":"C Poh","year":"2021","unstructured":"Poh C, Keegan T, Rosenberg AS. Second primary malignancies in multiple myeloma: a review. Blood Rev. 2021;46:100757.","journal-title":"Blood Rev"},{"key":"2707_CR3","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.1182\/bloodadvances.2022009212","volume":"7","author":"MB Geyer","year":"2023","unstructured":"Geyer MB, Shaffer BC, Bhatnagar B, Mims AS, Klein V, Dilip D, et al. Lenalidomide-associated B-cell ALL: clinical and pathologic correlates and sensitivity to lenalidomide withdrawal. Blood Adv. 2023;7:3087\u201398.","journal-title":"Blood Adv"},{"key":"2707_CR4","doi-asserted-by":"publisher","first-page":"4228","DOI":"10.1182\/bloodadvances.2019000925","volume":"3","author":"C Saygin","year":"2019","unstructured":"Saygin C, Kishtagari A, Cassaday RD, Reizine N, Yurkiewicz I, Liedtke M, et al. Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes. Blood Adv. 2019;3:4228\u201337.","journal-title":"Blood Adv"},{"key":"2707_CR5","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2204925","volume":"387","author":"PG Richardson","year":"2022","unstructured":"Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, et al. Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. N Engl J Med. 2022;387:132\u201347.","journal-title":"N Engl J Med"},{"key":"2707_CR6","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1158\/2643-3230.BCD-24-0103","volume":"5","author":"D Singhal","year":"2024","unstructured":"Singhal D, Kutyna MM, Hahn CN, Shah MV, Hiwase DK. Therapy-Related Myeloid Neoplasms: Complex Interactions among Cytotoxic Therapies, Genetic Factors, and Aberrant Microenvironment. Blood Cancer Discov. 2024;5:400\u201316.","journal-title":"Blood Cancer Discov"},{"key":"2707_CR7","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1158\/2643-3230.BCD-22-0154","volume":"4","author":"R Kim","year":"2023","unstructured":"Kim R, Bergugnat H, Larcher L, Duchmann M, Passet M, Gachet S, et al. Adult Low-Hypodiploid Acute Lymphoblastic Leukemia Emerges from Preleukemic TP53-Mutant Clonal Hematopoiesis. Blood Cancer Discov. 2023;4:134\u201349.","journal-title":"Blood Cancer Discov"},{"key":"2707_CR8","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1158\/2643-3230.BCD-23-0106","volume":"5","author":"C Saygin","year":"2024","unstructured":"Saygin C, Zhang P, Stauber J, Aldoss I, Sperling AS, Weeks LD, et al. Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis. Blood Cancer Discov. 2024;5:164\u201379.","journal-title":"Blood Cancer Discov"},{"key":"2707_CR9","doi-asserted-by":"publisher","first-page":"E223","DOI":"10.1002\/ajh.26170","volume":"96","author":"M Ozga","year":"2021","unstructured":"Ozga M, Blachly J, Eisfeld AK, Grieselhuber N, Larkin K, Walker A, et al. Type of prior genotoxic insult determines the genomic characteristics of therapy-related myeloid neoplasms. Am J Hematol. 2021;96:E223\u2013E5.","journal-title":"Am J Hematol"},{"key":"2707_CR10","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1182\/blood.2021014956","volume":"140","author":"AS Sperling","year":"2022","unstructured":"Sperling AS, Guerra VA, Kennedy JA, Yan Y, Hsu JI, Wang F, et al. Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms. Blood. 2022;140:1753\u201363.","journal-title":"Blood"},{"key":"2707_CR11","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S1470-2045(22)00738-0","volume":"24","author":"D Dytfeld","year":"2023","unstructured":"Dytfeld D, Wrobel T, Jamroziak K, Kubicki T, Robak P, Walter-Croneck A, et al. Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023;24:139\u201350.","journal-title":"Lancet Oncol"},{"key":"2707_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01156-x","volume":"14","author":"BA Derman","year":"2024","unstructured":"Derman BA, Major A, Cooperrider J, Jiang K, Ramsland A, Karrison T, et al. Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP). Blood Cancer J. 2024;14:170.","journal-title":"Blood Cancer J"},{"key":"2707_CR13","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/clpt.2008.89","volume":"84","author":"DM Roden","year":"2008","unstructured":"Roden DM, Pulley JM, Basford MA, Bernard GR, Clayton EW, Balser JR, et al. Development of a large-scale de-identified DNA biobank to enable personalized medicine. Clin Pharm Ther. 2008;84:362\u20139.","journal-title":"Clin Pharm Ther"},{"key":"2707_CR14","doi-asserted-by":"crossref","unstructured":"Mack T, Pershad Y, Vlasschaert C, Bejan CA, Heimlich JB, Li Y, et al. Germline genetics, disease, and exposure to medication influence longitudinal dynamics of clonal hematopoiesis. Haematologica. 2024;110:1010\u20138.","DOI":"10.3324\/haematol.2024.286513"},{"key":"2707_CR15","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1038\/s41591-018-0081-z","volume":"24","author":"P Desai","year":"2018","unstructured":"Desai P, Mencia-Trinchant N, Savenkov O, Simon MS, Cheang G, Lee S, et al. Somatic mutations precede acute myeloid leukemia years before diagnosis. Nat Med. 2018;24:1015\u201323.","journal-title":"Nat Med"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02707-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02707-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02707-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T11:46:42Z","timestamp":1757245602000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02707-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,16]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["2707"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02707-2","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,16]]},"assertion":[{"value":"7 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study adhered to the ethical guidelines set by institutional and\/or national research committees and complied with the principles outlined in the Declaration of Helsinki. All methods followed the applicable guidelines and regulations. The University of Chicago Institutional Review Board has approved the MRD2STOP and ATLAS clinical trials and the correlative research conducted with these samples. All participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and informed consent to participate"}}]}}